Stockscreener 앱 받기
15.82
1.67%
0.26
시간 외 거래:
15.89
0.07
+0.44%
전일 마감가:
$15.56
열려 있는:
$15.61
하루 거래량:
533.89K
Relative Volume:
0.66
시가총액:
$449.65M
수익:
$42.35M
순이익/손실:
$-78.67M
주가수익비율:
-5.6177
EPS:
-2.8161
순현금흐름:
$-63.18M
1주 성능:
+4.15%
1개월 성능:
+154.34%
6개월 성능:
+108.71%
1년 성능:
-5.61%
1일 변동 폭
$15.40
$16.02
1주일 범위
$14.00
$17.75
52주 변동 폭
$5.50
$24.17
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
명칭
Arcturus Therapeutics Holdings Inc
전화
(858) 900-2660
주소
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
15.82 | 312.37M | 42.35M | -78.67M | -63.18M | -2.8161 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 개시 | B. Riley Securities | Buy |
| 2026-01-23 | 개시 | Roth Capital | Buy |
| 2025-10-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-10-23 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-10-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-09-04 | 재개 | H.C. Wainwright | Buy |
| 2025-05-28 | 개시 | Scotiabank | Sector Outperform |
| 2025-01-28 | 개시 | BTIG Research | Buy |
| 2024-08-12 | 개시 | Leerink Partners | Outperform |
| 2023-12-13 | 개시 | Canaccord Genuity | Buy |
| 2023-07-24 | 개시 | William Blair | Outperform |
| 2023-05-11 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | 재개 | Wells Fargo | Overweight |
| 2022-11-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-11-02 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-08-10 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-05-11 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-01-31 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-08-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-06-25 | 재개 | Goldman | Neutral |
| 2021-06-21 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-02-17 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | 개시 | Wells Fargo | Overweight |
| 2020-12-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-12-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | 다운그레이드 | ROTH Capital | Buy → Sell |
| 2020-12-08 | 재확인 | B. Riley Securities | Buy |
| 2020-12-07 | 재확인 | B. Riley Securities | Buy |
| 2020-10-26 | 개시 | Barclays | Overweight |
| 2020-10-06 | 개시 | Citigroup | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-30 | 재개 | ROTH Capital | Buy |
| 2020-07-16 | 개시 | Raymond James | Outperform |
| 2020-07-13 | 개시 | B. Riley FBR | Buy |
| 2020-06-09 | 다운그레이드 | WBB Securities | Buy → Hold |
| 2020-02-11 | 개시 | Robert W. Baird | Outperform |
| 2020-02-07 | 개시 | Guggenheim | Buy |
| 2020-02-06 | 개시 | Guggenheim | Buy |
| 2019-04-05 | 개시 | H.C. Wainwright | Buy |
| 2018-09-20 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | 개시 | Chardan Capital Markets | Buy |
모두보기
Arcturus Therapeutics Holdings Inc 주식(ARCT)의 최신 뉴스
Precision Trading with Arcturus Therapeutics Holdings Inc. (ARCT) Risk Zones - Stock Traders Daily
Arcturus Therapeutics Holdings Inc. (ARCT) Peer Comparison – Compare with Others - valueresearchonline.com
Arcturus Therapeutics Holdings Inc (ARCT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Why is Arcturus Therapeutics stock surging today? By Investing.com - Investing.com Canada
Arcturus Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance
Arcturus, Moderna down on BioNTech trial setback (ARCT:NASDAQ) - Seeking Alpha
Arcturus Therapeutics Holdings Inc. (ARCT) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Arcturus Therapeutics Highlights ARCT-810 Progress at Metabolic Symposium - TipRanks
ARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’ - stocktwits.com
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Arcturus (ARCT) Results Review: EPS Comes in Above Forecast in the Latest Reading; Stock Move: The Market Price Advances 19.85% on the DayGeographic Revenue Trends - Vinanet
ARCT Stock Jumps As Vaccine Rights Return And Cash Pile Grows - StocksToTrade
ARCT Stock Jumps As Canaccord Backs Vaccine Reset - timothysykes.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Liquidity Mapping Around (ARCT) Price Events - Stock Traders Daily
We're Keeping An Eye On Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate - Moomoo
Dimensional Fund Advisors LP Decreases Holdings in Arcturus Therapeutics Holdings Inc. $ARCT - MarketBeat
Arcturus Therapeutics (ARCT) Surges 5.92% to $8.05, Approaches Key Resistance at $8.45Low Volatility Picks - vinanet.vn
HC Wainwright Has Optimistic Outlook of ARCT Q3 Earnings - MarketBeat
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline - MarketBeat
H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Hold Rating, Maintains Target Price $9 - Moomoo
BTIG Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Arcturus Therapeutics (NASDAQ:ARCT) Rating Increased to Sell at Wall Street Zen - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Announces Earnings Results, Beats Estimates By $0.16 EPS - MarketBeat
A Quick Look at Today's Ratings for Arcturus Therapeutics(ARCT.US), With a Forecast Between $20 to $20 - Moomoo
Arcturus Therapeutics Holdings Inc. Stock 12‑Month Price Target Cut to $20.2, Implies 232% Upside - TradingView
CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Cuts Target Price to $20 - Moomoo
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress - BioSpace
ARCT Looks 57.9% Overvalued on GF Value™ - GuruFocus
Earnings call transcript: Arcturus Therapeutics tops Q2 2026 EPS view By Investing.com - Investing.com South Africa
Arcturus Therapeutics Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: Arcturus Therapeutics tops Q2 2026 EPS view - Investing.com
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Arcturus Therapeutics Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Arcturus Therapeutics Holdings Inc. Q2 2026: Revenue $2.96M, EPS $(0.84) — 10-Q Summary - TradingView
Q2 2026 Arcturus Therapeutics Holdings Inc Earnings Call Transcript - GuruFocus
Arcturus Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Arcturus Therapeutics reports Q2 2026: $3.0M revenue, $23.8M net loss, $191.5M cash - TradingView
Arcturus Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Why (ARCT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Earnings To Watch: Arcturus Therapeutics Holdings Inc (ARCT) Q2 2026 -- GF Value Sees 44% Downside - Yahoo Finance
Arcturus Therapeutics Holdings Inc expected to post a loss of 100 cents a shareEarnings Preview - TradingView
ARCT Q1 2026 Earnings: Loss Narrower Than Expected as Shares Dip 2.7%Earnings Quality Score - Vinanet
Arcturus Therapeutics (NASDAQ:ARCT) Downgraded to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Arcturus Therapeutics (ARCT) to Announce Quarterly Earnings on Thursday - MarketBeat
Arcturus Therapeutics (ARCT) Slips 0.61% as Stock Hovers Near Key Support LevelMomentum ETF - vinanet.vn
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026 - Yahoo Finance
Arcturus Therapeutics Holdings Inc - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.86%
0.31%
자본화:
|
볼륨(24시간):